In 2020, the epidemic of COVID-19 has spread in the whole world, and COVID-19 diagnostic kit is definitely a purchasing point from the beginning. HUKUI Bio has been authorized by two Taiwan nucleic acid diagnostic kit factories to begin providing COVID-19 diagnostic kit for Europe, ASEAN and South America markets, hoping to satisfy their local medical resources.
HUKUI Bio CEO, Michael Kuo said, “Because of the U.S.-China trade war and epidemic COVID-19, the global medical device demand and supply will be overwhelmed changed.” After obtaining investment from European private equity fund- YELLOWSTONE at the end of last year, HUKUI Bio expands the business to worldwide medical device design, registration and manufacturing service. HUKUI Bio integrates its network with design/production/regulation ability in China and Taiwan market to provide worldwide medical device registration, including TFDA, NMPA, ISO 13485, GMP consultant, and OEM/ODM service, even Asian market development.
Today, the epidemic of COVID-19 is spreading around the world. Many areas are searching support from medical advanced countries such as Taiwan. HUKUI Bio is selling COVID-19 diagnostic kit to ASEAN countries through its network. Meanwhile, HUKUI Bio is looking for more products to provide the best support in order to accomplish the serious epidemic prevention task. Although Taiwan biomedical companies have outstanding R&D performance, they still need to work further to get certification soon. After that, it can speed up the export business and have Taiwan made diagnostic kits well known internationally.